Molnupiravir versus favipiravir in at-risk outpatients with COVID-19: a randomized controlled trial in Thailand
Description
CONCLUSIONS: Favipiravir and molnupiravir had a similar efficacy and safety profile. Whether either of the two reduced the risk of complications during the omicron era in this population with a low risk of pulmonary involvement and a high vaccine
